

**Reference:** FOI.ICB-2223/078

**Subject:** Funding for Multiple Sclerosis (MS)

*I can confirm that the ICB does hold some of the information requested; please see responses below:*

QUESTION	RESPONSE
1. How many people in your area have been diagnosed with MS?	<p>The ICB does not have a list of all patients who have been diagnosed with MS.</p> <p>Secondary Uses Service data held by the ICB indicates that in the 12-month period ending 31/08/2022:</p> <ul style="list-style-type: none"><li>- 449 patients had at least one elective admission, where MS was recorded in the diagnosis code field (in any diagnosis position)</li><li>- 348 patients had at least one emergency (non-elective) admission where MS was recorded in the diagnosis code field (in any diagnosis position)</li><li>- 3 patients had an outpatient appointment where MS was recorded in the primary diagnosis field.</li></ul> <p>The inclusion of an MS flag means this was a condition treated or investigated during the episode of healthcare.</p>

	<p>The data includes BNSSG ICB registered or resident patients who attended a secondary care acute setting in the BNSSG ICB area or outside the BNSSG area. It also includes patients registered/resident in an area other than BNSSG who attended a secondary care acute setting in the BNSSG area. Patients may appear in more than one care setting (elective/non-elective/outpatient).</p> <p>ICD10 code G35 used to identify patients.</p>
<p>2. If possible, please provide a breakdown of those with Remitting MS and those with Progressive MS (including Secondary Progressive).</p>	<p>This information will be held by North Bristol NHS Trust (NBT)</p> <p>Details of how to contact NBT can be found via the following link: <a href="https://www.nbt.nhs.uk/about-us/information-governance/freedom-information/request-information">https://www.nbt.nhs.uk/about-us/information-governance/freedom-information/request-information</a></p>
<p>3. If possible, please provide a breakdown of 2) above showing those that are Male or Female and age (within bands of 10 years from 0 upwards).</p>	
<p>4. What is the total annual funding provided in respect of MS. Please provide a breakdown of the funding that relates to “core service provision” and the amount that relates to individual treatment (such as cost of medication, etc).</p>	<p>This information will be held by NBT and NHS England Specialised Services (<a href="https://www.england.nhs.uk/commissioning/spec-services/">https://www.england.nhs.uk/commissioning/spec-services/</a>).</p>
<p>5. If funding is being used for the provision of medication, please say what the average annual spend is for those patients who have Remitting MS and those that have Progressive MS (if data is available).</p>	<p>NBT: <a href="https://www.nbt.nhs.uk/about-us/information-governance/freedom-information/request-information">https://www.nbt.nhs.uk/about-us/information-governance/freedom-information/request-information</a></p> <p>NHS England: <a href="https://www.england.nhs.uk/contact-us/foi/">https://www.england.nhs.uk/contact-us/foi/</a></p>

<p>6. In relation to those patients who have Secondary Progressive MS, do you help fund the cost of the patient receiving Siponimod (Mayzent). If yes, please provide the total number of cases where funding is being provided and average annual spend. If you do not provide funding for such cases, would you consider to do so if the patient contributed towards the funding?</p>	<p>The ICB does not commission treatment for Multiple Sclerosis. This information will be held by NHS England Specialised Services.</p> <p>NHS England: <a href="https://www.england.nhs.uk/contact-us/foi/">https://www.england.nhs.uk/contact-us/foi/</a></p>
<p>7. If known, do you contribute towards the domiciliary care costs of patients who have Progressive MS (including Secondary Progressive). If so, please say the average annual spend.</p>	<p>The ICB does not have the ability to code Continuing Care service users by diagnosis, therefore it is not possible to identify whether we contribute towards domiciliary care costs.</p>

***The information provided in this response is accurate as of 24 October 2022 and has been approved for release by Jon Lund, Deputy Chief Finance Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.***